HIGHLIGHTS
4457 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations
4459 Unmasking New Promises: Expanding the Antigen Landscape For Antibody-Drug Conjugates
Honey K. Oberoi and Elena Garralda
See related article, p. 4521

4462 TP53 Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?
Riccardo Bomben, Antonella Zucchetto, Massimo Gentile, and Valter Gathei
See related article, p. 4531

4465 Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia
Clive S. Zent
See related article, p. 4624

Review
4468 Facts and Hopes in Multiple Myeloma Immunotherapy
Adam S. Sperling and Kenneth C. Anderson

CCR Drug Updates
4478 FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

PERSPECTIVES
4486 A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes
David A. Potter, Alexandra Thomas, and Hope S. Rugo

CLINICAL TRIALS: TARGETED THERAPY

4491 Vorosidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma: Results of a First-in-Human Phase I Trial
Ingo K. Mellinghoff, Marta Penas-Prado, Katherine B. Peters, Howard A. Burris III, Elizabeth A. Maher, Filip Janku, Gregory M. Cote, Macarena I. de la Fuente, Jennifer L. Clarke, Benjamin M. Ellingson, Saewon Chun, Robert J. Young, Hua Liu, Sung Choe, Min Lu, Kha Le, Islam Hassan, Lori Steelman, Shuchi S. Pandya, Timothy F. Cloughesy, and Patrick Y. Wen

4500 Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

4511 First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>4521</td>
<td>Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies</td>
</tr>
<tr>
<td>4531</td>
<td>Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib</td>
</tr>
<tr>
<td>4539</td>
<td>Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Depression Therapy as They Progress to Metastatic Disease</td>
</tr>
<tr>
<td>4549</td>
<td>Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer</td>
</tr>
<tr>
<td>4557</td>
<td>Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck</td>
</tr>
<tr>
<td>4566</td>
<td>A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer</td>
</tr>
<tr>
<td>4574</td>
<td>Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer</td>
</tr>
<tr>
<td>4587</td>
<td>Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer</td>
</tr>
<tr>
<td>4599</td>
<td>Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guerin Immunotherapy in Non-Muscle-Invasive Bladder Cancer</td>
</tr>
</tbody>
</table>

### PRECISION MEDICINE AND IMAGING

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>4557</td>
<td>Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck</td>
</tr>
</tbody>
</table>

### CLINICAL TRIALS: IMMUNOTHERAPY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>4521</td>
<td>Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies</td>
</tr>
<tr>
<td>4557</td>
<td>Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck</td>
</tr>
</tbody>
</table>

### CLINICAL TRIALS: CLINICAL TRIALS: IMMUNOTHERAPY
**TRANSLATIONAL CANCER MECHANISMS AND THERAPY**

4610  Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition

4624  Select Antitumor Cytotoxic CD8\(^+\) T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Maria Joao Baptista, Sivasubramanian Baskar, Erik M. Gaglione, Keyvan Keyvanfar, Inhye E. Ahn, Adrian Wiestner, and Clare Sun

See related commentary, p. 4465

4634  Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
Munawar Anwar, Qitong Chen, Dengjie Ouyang, Shouman Wang, Ning Xie, Quchang Ouyang, Peizhi Fan, Liyuan Qian, Gannong Chen, Enxiang Zhou, Lei Guo, Xiaowen Gu, Boning Ding, Xiaohong Yang, Liping Liu, Chao Deng, Zhi Xiao, Jing Li, Yunqi Wang, Shan Zeng, Jinhui Hu, Wei Zhou, Bo Qui, Zhongming Wang, Jie Weng, Mingwen Liu, Yi Li, Tiegang Tang, Jianguo Wang, Hui Zhang, Bin Dai, Wuping Tang, Tao Wu, Maoliang Xiao, Xiantao Li, Hailong Liu, Lai Li, and Wenjun Yi

**CORRECTION**

4664  Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
Justine S. Paradis, Monica Acosta, Robert Saddawi-Konefka, Ayush Kishore, Simone Lubrano, Frederico Gomes, Nadia Arang, Manuela Tiago, Silvia Coma, Xingyu Wu, Kyle Ford, Chi-Ping Day, Glenn Merlino, Prashant Mali, Jonathan A. Pachter, Takamii Sato, Andrew E. Aplin, and J. Silvio Gutkind
ABOUT THE COVER

The cover shows a section of a pretherapeutic tumor sample from a patient with metastatic melanoma. Immunohistochemical staining shows T- and B-lymphocyte interactions in the stroma compartment by dual CD3/CD19 staining. Connected bands represent spatial proximity distribution. For details, see the article by Brase and colleagues on page 4500 of this issue.